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Introduction
Biodegradable polymer carriers offer attractive features
for therapeutic cancer vaccines including delivery of
multiple vaccine components, efficient internalization,
and sustained release of adjuvants and tumor-associated
antigens (TAAs). We previously demonstrated that local
delivery of depots containing nucleic acid-based toll-
liked receptor agonists (TLRas) to lymph nodes (LNs)
potently enhances antigen-specific T cell immunity.
Building on this work, we hypothesized that local LN
delivery of microparticles loaded with TAA-encoding
plasmid DNA (pDNA) and TLRas might drive strong
local expression and presentation of antigen by LN-resi-
dent antigen presenting cells. These effects could help
drive more potent and effective CD8+ T cell functions
that slow or stop tumor growth.
Methods
Plasmids were designed and synthesized to encode
model reporter genes or a conserved T cell peptide epi-
tope, TRP2 (SVYDFFVWL) for human and murine mel-
anoma. Screening studies with primary dendritic cells
utilized poly(lactic-co-glycolide) microparticles synthe-
sized by water-oil-water emulsion, stabilized with polyvi-
nyl alcohol. The inner aqueous phase was loaded with a
TLR9 agonist (CpG oligodeoxynucleotide) and pDNA.
Size and loading were characterized by laser diffraction
and UV-vis spectroscopy. Murine splenocytes expressing
CD11c were harvested, isolated, and treated overnight in
triplicate with empty particles or particles encapsulating
CpG only, pDNA only, or both CpG+pDNA. Cells were
analyzed by flow cytometry using markers for viability
(DAPI-) and dendritic cell activation (CD40+, CD80+,
CD86+).
Results
The pDNA vector for the TRP2 epitope was designed to
express degradable peptide spacers (AAY) flanking
repeating units of the antigenic epitope. This vector was
synthesized with and without a sequence encoding ubi-
quitin to provide efficient proteasomal peptide proces-
sing and antigen expression. Particles exhibited mean
diameters 2.5-4.4µm depending on cargo and synthesis
energy. Cargo loading was measured for CpG particles
at 3.8µg CpG/mg particles and for pDNA particles at
11.1µg pDNA/mg particles. During ex vivo screening,
particles containing cargo increased CD40, CD80, and
CD86 expression compared to empty particles and did
not impact cell viability compared to controls treated
with soluble TLRas.
Discussion
Initial studies demonstrate microparticles loaded with
TLRa and pDNA effectively stimulate primary immune
cells, supporting a platform for loading and driving local
TAA expression alongside vaccine components like
TLRas. Ongoing studies will assess gene expression
levels in primary cells and secondary lymph organs
using a mouse melanoma model and will correlate local
TAA expression with antigen-specific T cell expansion
and efficacy during tumor challenge.
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